Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.

NCT02106338 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

NIH

Sponsor class

Conditions

Clostridium Difficile Infection

Interventions

OTHER: Placebo
DRUG: CRS3123

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)